Overview

  • Product nameAnti-BCOR antibody
    See all BCOR primary antibodies
  • Description
    Goat polyclonal to BCOR
  • SpecificityThis antibody is expected to recognise both reported isoforms (represented by NP_060215 and NP_065977).
  • Tested applicationsSuitable for: ICC/IF, ChIP, WBmore details
  • Species reactivity

    Predicted to work with: Mouse, Cow, Dog, Human, Pig
  • Immunogen

    Synthetic peptide: LSATPLYGNVHSW, corresponding to N terminal amino acids 2-14 of Human BCOR.

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab5276 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use at an assay dependent concentration. PubMed: 24146931
ChIP Use at an assay dependent concentration.
WB Use at an assay dependent concentration. Can be blocked with Human BCOR peptide (ab23093). Preliminary experiments gave no signal but low background in Human Testis and 293 cell lysates at up to 1µg/ml.

Target

  • FunctionTranscriptional corepressor. May specifically inhibit gene expression when recruited to promoter regions by sequence specific DNA-binding proteins such as BCL6 and MLLT3. This repression may be mediated at least in part by histone deacetylase activities which can associate with this corepressor. Involved in the repression of TFAP2A; impairs binding of BCL6 and KDM2B to TFAP2A promoter regions. Via repression of TFAP2A acts as a negative regulator of osteo-dentiogenic capacity in adult stem cells; the function implies inhibition of methylation on histone H3 'Lys-4' (H3K4me3) and 'Lys-36' (H3K36me2).
  • Tissue specificityUbiquitously expressed.
  • Involvement in diseaseDefects in BCOR are the cause of microphthalmia syndromic type 2 (MCOPS2) [MIM:300166]. Microphthalmia is a clinically heterogeneous disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities. MCOPS2 is a very rare multiple congenital anomaly syndrome characterized by eye anomalies (congenital cataract, microphthalmia, or secondary glaucoma), facial abnormalities (long narrow face, high nasal bridge, pointed nose with cartilages separated at the tip, cleft palate, or submucous cleft palate), cardiac anomalies (atrial septal defect, ventricular septal defect, or floppy mitral valve) and dental abnormalities (canine radiculomegaly, delayed dentition, oligodontia, persistent primary teeth, or variable root length).
  • Sequence similaritiesBelongs to the BCOR family.
    Contains 3 ANK repeats.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • 5830466J11Rik antibody
    • 8430401K06Rik antibody
    • ANOP 2 antibody
    • ANOP2 antibody
    • BCL 6 co repressor antibody
    • BCL 6 corepressor antibody
    • BCL 6 interacting corepressor antibody
    • BCL-6 corepressor antibody
    • BCL6 co repressor antibody
    • BCL6 corepressor antibody
    • BCL6 interacting corepressor antibody
    • BCoR antibody
    • BCOR_HUMAN antibody
    • FLJ20285 antibody
    • FLJ38041 antibody
    • KIAA1575 antibody
    • MAA 2 antibody
    • MAA2 antibody
    • MCOPS 2 antibody
    • MCOPS2 antibody
    • MGC131961 antibody
    • MGC71031 antibody
    see all

References for Anti-BCOR antibody (ab5276)

This product has been referenced in:
  • Buchberger E  et al. Overexpression of the Transcriptional Repressor Complex BCL-6/BCoR Leads to Nuclear Aggregates Distinct from Classical Aggresomes. PLoS One 8:e76845 (2013). ICC/IF . Read more (PubMed: 24146931) »

See 1 Publication for this product

Product Wall

Thank you for contacting us.

The blocking peptide is available with catalogue number ab23093; http://www.abcam.com/BCOR-peptide-2-14-ab23093.html

I hope this information is helpful to you. Please do not hesitate to contact us if you n...

Read More
Abcam has not validated the combination of species/application used in this Abreview.
Application Immunocytochemistry/ Immunofluorescence
Sample Mouse Cell (Whole-Mount Morula Stage Embryos)
Specification Whole-Mount Morula Stage Embryos
Fixative Paraformaldehyde
Permeabilization Yes - 0.1% Triton-X in PBS
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 2% · Temperature: 20°C
Username

Abcam user community

Verified customer

Submitted Mar 01 2011

Abcam has not validated the combination of species/application used in this Abreview.
Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (human epithelial kidney cells)
Specification human epithelial kidney cells
Fixative Paraformaldehyde
Permeabilization Yes - triton-x
Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 20°C
Username

Abcam user community

Verified customer

Submitted May 19 2008

Abreviews
Application ChIP
Sample Human Cell lysate - nuclear (HEK)
Specification HEK
Type Cross-linking (X-ChIP)
Duration of cross-linking step: 5 minute(s) and 0 second(s)
Specification of the cross-linking agent: 1% formaldhye
Detection step Semiquantitative PCR
Positive control anti-acetyl-histone H3
Negative control IgG control
Username

Abcam user community

Verified customer

Submitted May 01 2008

Thank you for your enquiry. We would greatly appreciate your feedback on these antibodies, whether positive or negative. We will award 1,000 Abcam points to the first researcher who sends us positive feedback (including an image and details of material...

Read More

We do not routinely offer free or trial sized samples for testing purposes. Our policy at Abcam is that if an antibody does not work as specified on the datasheet, we will offer a replacement or reimbursement. Should you decide to test an antibody ...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"